New Delhi: Russia’s vaccine Sputnik V has shown strong immunity in the third phase trial. 91.6% Efficacy Rate has been revealed in the results. Russia’s Direct Investment Fund Department has stated that these results are interim yet. Kirill Dmitriev of the department has said that India is a major partner in vaccine production and distribution. Along with this, there is also the possibility of giving exemption of emergency use in India till this month or next month.
Emergency in India can apply for use Sputnik V
Some time ago there was news that Sputnik V vaccine may soon apply for emergency use. The head of the National Covid Task Force, Dr. Vinod Paul had told that Sputnik’s last phase trial is going on in India. After this result can be applied for emergency use of Sputnik.
Russia announced to make vaccine first in the world
Significantly, in the month of August, Russia had announced to make of the world’s first corona vaccine. However, experts had also expressed concern about the trial results. In India too, the third phase trial of this vaccine was allowed in the middle of January. The DCGI allowed Dr. Reddy Laboratories to conduct a third phase trial of the corona vaccine. GV Prasad, co-chairman and managing director of Dr. Reddy’s Laboratories, said that this is the most important step in the clinical trial of vaccines. He said that Dr. Reddy’s Lab will start the third and final phase this month.
